Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, Fernández RA, Bittrich M, Ruiz-Heredia Y, Da Viá M, Zovko J, Garitano-Trojaola A, Bolli N, Ruckdeschel A, Stühmer T, Chatterjee M, Kull M, Krönke J, Agirre X, Martin-Subero JI, Raab P, Einsele H, Rasche L, Martinez-Lopez J, Haaf T, Kortüm KM. Haertle L, et al. Among authors: kull m. Blood. 2021 Nov 4;138(18):1721-1726. doi: 10.1182/blood.2020010452. Blood. 2021. PMID: 34115836 Free PMC article.
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Kortüm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Kortüm KM, et al. Among authors: kull m. Br J Haematol. 2015 Feb;168(4):507-10. doi: 10.1111/bjh.13171. Epub 2014 Oct 10. Br J Haematol. 2015. PMID: 25302557 Free PMC article.
The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.
Weißbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M, Bargou R, Einsele H, Rosenwald A, Knop S, Leich E. Weißbach S, et al. Among authors: kull m. Br J Haematol. 2015 Apr;169(1):57-70. doi: 10.1111/bjh.13256. Epub 2014 Dec 17. Br J Haematol. 2015. PMID: 25521164 Free article. Clinical Trial.
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
Kortüm KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX, Jedlowski P, Egan JB, Ojha J, Bullinger L, Kull M, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Kortüm KM, et al. Among authors: kull m. Ann Hematol. 2015 Jul;94(7):1205-11. doi: 10.1007/s00277-015-2344-9. Epub 2015 Mar 7. Ann Hematol. 2015. PMID: 25743686 Free PMC article.
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D, Greiner A, Kolmus S, Köpff S, Schreder M, Mügge LO, Straka C, Engelhardt M, Döhner H, Einsele H, Bassermann F, Bargou R, Knop S, Langer C. Krönke J, et al. Among authors: kull m. Leukemia. 2017 Jun;31(6):1363-1367. doi: 10.1038/leu.2016.384. Epub 2016 Dec 26. Leukemia. 2017. PMID: 28017969 Clinical Trial.
Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany.
Engelhardt M, Shoumariyeh K, Rösner A, Ihorst G, Biavasco F, Meckel K, von Metzler I, Treurich S, Hebart H, Grube M, Kull M, Bassermann F, Schäfer-Eckart K, Hoferer A, Einsele H, Rasche L, Wäsch R. Engelhardt M, et al. Among authors: kull m. Haematologica. 2020 Dec 1;105(12):2872-2878. doi: 10.3324/haematol.2020.262758. Haematologica. 2020. PMID: 33256391 Free PMC article. No abstract available.
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Bohl SR, Schmalbrock LK, Bauhuf I, Meyer T, Dolnik A, Szyska M, Blätte TJ, Knödler S, Röhner L, Miller D, Kull M, Langer C, Döhner H, Letai A, Damm F, Heckl D, Bullinger L, Krönke J. Bohl SR, et al. Among authors: kull m. Blood Adv. 2021 May 11;5(9):2391-2402. doi: 10.1182/bloodadvances.2020003541. Blood Adv. 2021. PMID: 33950175 Free PMC article.
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, Müller S, Popp O, Kull M, Haji M, Gütschow M, Döhner H, Walther W, Keller U, Bullinger L, Mertins P, Krönke J. Ng YLD, et al. Among authors: kull m. Nat Commun. 2022 Feb 23;13(1):1009. doi: 10.1038/s41467-022-28515-1. Nat Commun. 2022. PMID: 35197447 Free PMC article.
112 results